Literature DB >> 32366710

Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm Model.

Hajira Bilal1, Phillip J Bergen1, Jessica R Tait1, Steven C Wallis2, Anton Y Peleg3, Jason A Roberts2,4,5,6, Antonio Oliver7, Roger L Nation8, Cornelia B Landersdorfer9.   

Abstract

Treatment of exacerbations of chronic Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF) is highly challenging due to hypermutability, biofilm formation, and an increased risk of resistance emergence. We evaluated the impact of ciprofloxacin and meropenem as monotherapy and in combination in the dynamic in vitro CDC biofilm reactor (CBR). Two hypermutable P. aeruginosa strains, PAOΔmutS (MIC of ciprofloxacin [MICciprofloxacin], 0.25 mg/liter; MICmeropenem, 2 mg/liter) and CW44 (MICciprofloxacin, 0.5 mg/liter; MICmeropenem, 4 mg/liter), were investigated for 120 h. Concentration-time profiles achievable in epithelial lining fluid (ELF) following FDA-approved doses were simulated in the CBR. Treatments were ciprofloxacin at 0.4 g every 8 h as 1-h infusions (80% ELF penetration), meropenem at 6 g/day as a continuous infusion (CI) (30% and 60% ELF penetration), and their combinations. Counts of total and less-susceptible planktonic and biofilm bacteria and MICs were determined. Antibiotic concentrations were quantified by an ultrahigh-performance liquid chromatography photodiode array (UHPLC-PDA) assay. For both strains, all monotherapies failed, with substantial regrowth and resistance of planktonic (≥8 log10 CFU/ml) and biofilm (>8 log10 CFU/cm2) bacteria at 120 h (MICciprofloxacin, up to 8 mg/liter; MICmeropenem, up to 64 mg/liter). Both combination treatments demonstrated synergistic bacterial killing of planktonic and biofilm bacteria of both strains from ∼48 h onwards and suppressed regrowth to ≤4 log10 CFU/ml and ≤6 log10 CFU/cm2 at 120 h. Overall, both combination treatments suppressed the amplification of resistance of planktonic bacteria for both strains and of biofilm bacteria for CW44. The combination with meropenem at 60% ELF penetration also suppressed the amplification of resistance of biofilm bacteria for PAOΔmutS Thus, combination treatment demonstrated synergistic bacterial killing and resistance suppression against difficult-to-treat hypermutable P. aeruginosa strains.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  antibiotic resistance; biofilm infection; combination therapy; hypermutator

Mesh:

Substances:

Year:  2020        PMID: 32366710      PMCID: PMC7318014          DOI: 10.1128/AAC.00469-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  57 in total

Review 1.  Bacterial biofilms: a common cause of persistent infections.

Authors:  J W Costerton; P S Stewart; E P Greenberg
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

2.  In vitro activity of meropenem in combination with ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.

Authors:  Semiha Solak; Ayşe Willke; Onder Ergönül; Emin Tekeli
Journal:  Int J Antimicrob Agents       Date:  2005-02       Impact factor: 5.283

Review 3.  ECFS best practice guidelines: the 2018 revision.

Authors:  Carlo Castellani; Alistair J A Duff; Scott C Bell; Harry G M Heijerman; Anne Munck; Felix Ratjen; Isabelle Sermet-Gaudelus; Kevin W Southern; Jurg Barben; Patrick A Flume; Pavla Hodková; Nataliya Kashirskaya; Maya N Kirszenbaum; Sue Madge; Helen Oxley; Barry Plant; Sarah Jane Schwarzenberg; Alan R Smyth; Giovanni Taccetti; Thomas O F Wagner; Susan P Wolfe; Pavel Drevinek
Journal:  J Cyst Fibros       Date:  2018-03-03       Impact factor: 5.482

4.  The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.

Authors:  Ilknur Erdem; Jale Kaynar-Tascioglu; Birsen Kaya; Pasa Goktas
Journal:  Int J Antimicrob Agents       Date:  2002-11       Impact factor: 5.283

Review 5.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

6.  A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients.

Authors:  Jeffery T Zobell; David C Young; C Dustin Waters; Krow Ampofo; Jared Cash; Bruce C Marshall; Jared Olson; Barbara A Chatfield
Journal:  Pediatr Pulmonol       Date:  2011-04-25

7.  Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.

Authors:  Eric Wenzler; Mark H Gotfried; Jeffrey S Loutit; Stephanie Durso; David C Griffith; Michael N Dudley; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

Review 8.  Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

Authors:  Jason A Roberts; Mohd H Abdul-Aziz; Jeffrey Lipman; Johan W Mouton; Alexander A Vinks; Timothy W Felton; William W Hope; Andras Farkas; Michael N Neely; Jerome J Schentag; George Drusano; Otto R Frey; Ursula Theuretzbacher; Joseph L Kuti
Journal:  Lancet Infect Dis       Date:  2014-04-24       Impact factor: 25.071

9.  Pseudomonas aeruginosa: resistance to the max.

Authors:  Keith Poole
Journal:  Front Microbiol       Date:  2011-04-05       Impact factor: 5.640

10.  Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial.

Authors:  Adela Benítez-Cano; Sonia Luque; Luisa Sorlí; Jesús Carazo; Isabel Ramos; Nuria Campillo; Víctor Curull; Albert Sánchez-Font; Carles Vilaplana; Juan P Horcajada; Ramón Adalia; Silvia Bermejo; Enric Samsó; William Hope; Santiago Grau
Journal:  Crit Care       Date:  2020-02-17       Impact factor: 9.097

View more
  2 in total

1.  Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.

Authors:  Hajira Bilal; Jessica R Tait; Yinzhi Lang; Jieqiang Zhou; Phillip J Bergen; Anton Y Peleg; Jürgen B Bulitta; Antonio Oliver; Roger L Nation; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2022-01-18       Impact factor: 5.938

2.  Clinically Relevant Concentrations of Polymyxin B and Meropenem Synergistically Kill Multidrug-Resistant Pseudomonas aeruginosa and Minimize Biofilm Formation.

Authors:  Hasini Wickremasinghe; Heidi H Yu; Mohammad A K Azad; Jinxin Zhao; Phillip J Bergen; Tony Velkov; Qi Tony Zhou; Yan Zhu; Jian Li
Journal:  Antibiotics (Basel)       Date:  2021-04-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.